Validation of two generic patient-reported outcome measures in patients with type 2 diabetes

Louis S Matza, Kristina S Boye, Nicole Yurgin, Louis S Matza, Kristina S Boye, Nicole Yurgin

Abstract

Background: Prior to using a generic patient-reported outcome measure (PRO), the measure should be validated within the target population. The purpose of the current study was to validate two generic measures in patients with type 2 diabetes.

Methods: Patients with type 2 diabetes in Scotland and England completed two generic measures: EQ-5D and Psychological General Well-Being Index (PGWB). Two diabetes-specific measures were administered: ADS and DSC-R. Analyses assessed reliability and validity.

Results: There were 130 participants (53 Scotland; 77 England; 64% male; mean age = 55.7 years). Responses on the EQ-5D and PGWB reflected moderate impairment consistent with previous diabetes samples: mean EQ-5D Index score, 0.75; EQ-5D VAS, 68.8; PGWB global score, 67.9. All scales of the PGWB demonstrated good internal consistency reliability (Cronbach's alpha = 0.77 to 0.97). The EQ-5D and PGWB demonstrated convergent validity through significant correlations with the ADS (r = 0.48 to 0.61), DSC-R scales (r = 0.33 to 0.81 except ophthalmology subscale), and Body Mass Index (r = 0.15 to 0.38). The EQ-5D and PGWB discriminated between groups of patients known to differ in diabetes-related characteristics (e.g., history of hypoglycemia).

Conclusion: Results support the use of the EQ-5D and PGWB among patients with type 2 diabetes, possibly in combination with condition-specific measures.

References

    1. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13–35. doi: 10.2165/00019053-200017010-00002.
    1. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622–629.
    1. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217–32. doi: 10.1097/00005650-198903001-00018.
    1. Kalpaklioglu AF, Kara T, Kurtipek E, Kocyigit P, Ekici A, Ekici M. Evaluation and impact of chronic cough: comparison of specific vs generic quality-of-life questionnaires. Ann Allergy Asthma Immunol. 2005;94:581–585.
    1. Leong KP, Yeak SC, Saurajen AS, Mok PK, Earnest A, Siow JK, Chee NW, Yeo SB, Khoo ML, Lee JC, Seshadri R, Chan SP, Tang CY, Chng HH. Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clin Exp Allergy. 2005;35:288–298. doi: 10.1111/j.1365-2222.2005.02201.x.
    1. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56:52–60. doi: 10.1016/S0895-4356(02)00537-1.
    1. Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52:187–192. doi: 10.1016/S0895-4356(98)00157-7.
    1. Graue M, Wentzel-Larsen T, Hanestad BR, Batsvik B, Sovik O. Measuring self-reported, health-related, quality of life in adolescents with type 1 diabetes using both generic and disease-specific instruments. Acta Paediatr. 2003;92:1190–1196. doi: 10.1080/08035250310005657.
    1. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health. 1999;2:113–127. doi: 10.1046/j.1524-4733.1999.02210.x.
    1. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE., Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478–1487. doi: 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>;2-M.
    1. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69:67–73. doi: 10.1136/jnnp.69.1.67.
    1. Brennan DS, Spencer AJ. Comparison of a generic and a specific measure of oral health related quality of life. Community Dental Health. 2004;22:11–18.
    1. Iglesias CP, Birks Y, Nelson EA, Scanlon E, Cullum NA. Quality of life of people with venous leg ulcers: a comparison of the discriminative and responsive characteristics of two generic and a disease specific instruments. Qual Life Res. 2005;14:1705–1718. doi: 10.1007/s11136-005-2751-9.
    1. Katsura H, Yamada K, Kida K. Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med. 2005;99:624–630. doi: 10.1016/j.rmed.2004.09.017.
    1. Michalak EE, Tam EM, Manjunath CV, Solomons K, Levitt AJ, Levitan R, Enns M, Morehouse R, Yatham LN, Lam RW. Generic and health-related quality of life in patients with seasonal and nonseasonal depression. Psychiatry Res. 2004;128:245–251. doi: 10.1016/j.psychres.2004.01.012.
    1. Yilmaz B, Goktepe AS, Alaca R, Mohur H, Kayar AH. Comparison of a generic and a disease specific quality of life scale to assess a comprehensive spa therapy program for knee osteoarthritis. Joint Bone Spine. 2004;71:563–566. doi: 10.1016/j.jbspin.2003.09.008.
    1. Engstrom CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J. 2001;18:69–76. doi: 10.1183/09031936.01.00044901.
    1. Brommels M, Sintonen H. Be generic and specific: quality of life measurement in clinical studies. Ann Med. 2001;33:319–322.
    1. Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. J Clin Epidemiol. 1997;50:557–569. doi: 10.1016/S0895-4356(97)00001-2.
    1. de Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG. Trends in the prevalence and management of diagnosed type 2 diabetes 1994-2001 in England and Wales. BMC Fam Pract. 2005;6:13. doi: 10.1186/1471-2296-6-13.
    1. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829–834. doi: 10.2337/diacare.25.5.829.
    1. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care. 1997;20:562–567. doi: 10.2337/diacare.20.4.562.
    1. Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract. 1998;42:17–27. doi: 10.1016/S0168-8227(98)00085-0.
    1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431. doi: 10.2337/diacare.21.9.1414.
    1. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001;4:392–400. doi: 10.1046/j.1524-4733.2001.45029.x.
    1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79. doi: 10.1001/jama.289.1.76.
    1. Varughese GI, Tomson J, Lip GY. Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract. 2005;59:798–816. doi: 10.1111/j.1368-5031.2005.00571.x.
    1. Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht, Kluwer Academic Publishers; 2003.
    1. EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217–230. doi: 10.1002/hec.910.
    1. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med Decis Making. 2002;22:340–349. doi: 10.1177/027298902400448902.
    1. Koopmanschap M. Coping with Type II diabetes: the patient's perspective. Diabetologia. 2002;45:S18–22.
    1. Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med. 2005;22:1482–1486. doi: 10.1111/j.1464-5491.2005.01657.x.
    1. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458–463. doi: 10.2337/diacare.25.3.458.
    1. UK Prospective Diabetes Study Group (UKPDS) Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37) Diabetes Care. 1999;22:1125–1136. doi: 10.2337/diacare.22.7.1125.
    1. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger, N. K., Mattson, M. E., Furberg, C. D. and et al., editor. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Washington, DC, Le Jacq Publishing; 1984. pp. 170–183.
    1. Herlitz J, Caidahl K, Wiklund I, Sjoland H, Karlson BW, Karlsson T, Haglid M, Hartford M. Impact of a history of diabetes on the improvement of symptoms and quality of life during 5 years after coronary artery bypass grafting. J Diabetes Complications. 2000;14:314–321. doi: 10.1016/S1056-8727(00)00115-X.
    1. Shobhana R, Rama Rao P, Lavanya A, Padma C, Vijay V, Ramachandran A. Quality of life and diabetes integration among subjects with type 2 diabetes. J Assoc Physicians India. 2003;51:363–365.
    1. Leonardson GR, Daniels MC, Ness FK, Kemper E, Mihura JL, Koplin BA, Foreyt JP. Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol Rep. 2003;93:49–58. doi: 10.2466/PR0.93.5.49-58.
    1. Krabbe P, Weijnen T. Guidelines for analysing and reporting EQ-5D outcomes. In: Brooks R, Rabin R and de Charro F, editor. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht, Kluwer Academic Publishers; 2003.
    1. McDowell I, Newell C. Measuring Health: A guide to rating scales and questionnaires. 2nd. New York, Oxford University Press; 1996.
    1. Chassany O, Dimenas E, Dubois D, Wu A. PGWBI User Manual. Lyon, France, MAPI Research Institute; 2004.
    1. Carey MP, Jorgensen RS, Weinstock RS, Sprafkin RP, Lantinga LJ, Carnrike CL, Jr., Baker MT, Meisler AW. Reliability and validity of the appraisal of diabetes scale. J Behav Med. 1991;14:43–51. doi: 10.1007/BF00844767.
    1. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med. 1994;11:253–261.
    1. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes. 1985;9:147–153.
    1. Centers for Disease Control and Prevention (CDC) Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004;53:1066–1068.
    1. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care. 2003;30:465–491.
    1. Bulpitt CJ, Palmer AJ, Battersby C, Fletcher AE. Association of symptoms of type 2 diabetic patients with severity of disease, obesity, and blood pressure. Diabetes Care. 1998;21:111–115. doi: 10.2337/diacare.21.1.111.
    1. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care. 1997;20:1744–1766.
    1. Scheen AJ. Treatment of diabetes in patients with severe obesity. Biomed Pharmacother. 2000;54:74–79. doi: 10.1016/S0753-3322(00)88855-1.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd. Hillsdale, NJ, Lawrence Erlbaum Associates; 1988.
    1. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care. 2005;28:1599–1603. doi: 10.2337/diacare.28.7.1599.
    1. Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med. 2002;19:1–11. doi: 10.1046/j.1464-5491.2002.00650.x.
    1. Luscombe FA. Health-related quality of life measurement in type 2 diabetes. Value Health. 2000;3 Suppl 1:15–28. doi: 10.1046/j.1524-4733.2000.36032.x.
    1. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887–900. doi: 10.1023/A:1008996223999.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する